港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

465.963

-0.190-0.04%

漲家數：10

跌家數：17

平家數：7

市盈率：- -

高：470.854

開：466.355

低：458.442

收：466.153

資料載入中...

2025年製藥、生物科技和生命科學行業上市公司G維度結果分析：基於2021-2023年度數據對比(上)

歐康維視生物-B(01477)4月30日斥資10.84萬港元回購2萬股

4月30日鵬華醫藥科技股票A淨值增長1.61%，今年來累計上漲34.72%

中新健康丨康方生物明星雙抗數據不及預期？回應來了

中国新闻网

加科思-B(01167)：一致行動人士可行使的投票權由約26.67%變為約25.21%

德商銀行：歐元區經濟增長勢頭可能轉瞬即逝

康寧傑瑞製藥-B(09966)：KN026關鍵性II/III期臨牀試驗期中分析達到PFS主要終點

歌禮制藥-B(01672)因購股權獲行使合計發行4.7萬股

和鉑醫藥-B(02142)4月30日斥資231.56萬港元回購27萬股

新諾威76億併購涼了，155億“石家莊大佬”還要死磕創新藥？

每日賣空追蹤 | 康寧傑瑞製藥-B 04月30日賣空量成交2000股，賣空比例為0.1%

每日賣空追蹤 | 科濟藥業-B 04月30日賣空量成交9萬股，賣空比例為7.78%

每日賣空追蹤 | 雲頂新耀-B 04月30日賣空量成交52.05萬股，賣空比例為9.79%

華仁藥業(300110.SZ)子公司取得一項醫療器械註冊證

榮昌生物：2022年A股限制性股票激勵計劃部分權益歸屬完成暨上市公告

對話於邱黎陽：讓科學家參與投資把關，能夠促成生命健康產業“投早投小”

21世纪经济报道

【華仁藥業：子公司取得醫療器械註冊證】華仁藥業公告，全資子公司青島華仁醫療用品有限公司收到山東省藥品監督管理局核准簽發的“醫用創面敷料”的《醫療器械註冊證》。該產品適用於非慢性創面及周圍皮膚護理，包含15個型號規格。目前國內擁有同類上市產品的企業共22家。本次取得註冊證將豐富公司醫療器械產品線，提高競爭力，助力公司原料藥、製劑、醫療器械、醫用包材等板塊的協同發展。

康哲藥業擬分拆德鎂醫藥上市，聚焦皮膚健康駛入增長“快車道”

环球财富网

康希諾生物04月30日主力淨流入393.0萬元散户資金拋售

基石藥業-B04月30日主力淨流出5.0萬元散户資金買入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":465.96255,"timestamp":1746000495831,"preClose":466.15277,"halted":0,"volume":90926529,"delay":0,"changeRate":-0.000408,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-0.190216,"latestTime":"04-30 16:00:00","open":466.35526,"high":470.85376,"low":458.44226,"amount":2573153749,"amplitude":0.026625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"pbRate":3.89505,"peRate":-23.354671,"turnoverRate":0.003412,"increases":10,"decrements":21,"flats":2,"marketCap":269853969728,"floatMarketCap":248722156224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":470.85376,"amplitude":0.026625,"preClose":466.15277,"low":458.44226,"pbRate":"3.89505","latestPrice":465.96255,"volume":90926529,"delay":0,"open":466.35526,"prevYearClose":331.1933,"prevWeekClose":490.526,"prevMonthClose":455.082,"prevQuarterClose":455.082,"fiveDayClose":475.823,"twentyDayClose":459.856,"sixtyDayClose":321.772,"secType":"PLATE","market":"HK","turnoverRate":0.003412,"peRate":-23.354671,"marketCap":269853969728,"floatMarketCap":248722156224,"timestamp":1746000495831,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":10,"down":17,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531079051","title":"2025年製藥、生物科技和生命科學行業上市公司G維度結果分析：基於2021-2023年度數據對比(上)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531079051","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531079051?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 22:51","pubTimestamp":1746024670,"startTime":"0","endTime":"0","summary":"整体上，近三年制药、生物科技和生命科学行业上市公司的ESG战略管理及制度建设情况呈持续上升趋势。","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2025/04/30/3eb3202e7818ad1bea0c273107722b66.jpeg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2025/04/30/3eb3202e7818ad1bea0c273107722b66.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://esg.jrj.com.cn/2025/04/30225150062599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","01477","BK1574","159837"],"gpt_icon":0},{"id":"2531030184","title":"歐康維視生物-B(01477)4月30日斥資10.84萬港元回購2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531030184","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531030184?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 21:21","pubTimestamp":1746019290,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，于2025年4月30日斥资10.84万港元回购2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2531032047","title":"4月30日鵬華醫藥科技股票A淨值增長1.61%，今年來累計上漲34.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531032047","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531032047?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 20:52","pubTimestamp":1746017527,"startTime":"0","endTime":"0","summary":"金融界2025年4月30日消息，鹏华医药科技股票A 最新净值1.3781元，增长1.61%。该基金近1个月收益率8.91%，同类排名3|1014；近3个月收益率34.48%，同类排名11|1011；今年来收益率34.72%，同类排名11|1001。公开资料显示，鹏华医药科技股票A基金成立于2015年6月2日，截至2025年3月31日，鹏华医药科技股票A规模19.49亿元，基金经理为金笑非。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30205250060055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1161","BK1574","159938","09939"],"gpt_icon":0},{"id":"2531185037","title":"中新健康丨康方生物明星雙抗數據不及預期？回應來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2531185037","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531185037?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 20:46","pubTimestamp":1746017192,"startTime":"0","endTime":"0","summary":"4月28日， 康方生物 召开线上业务沟通会回应“OS期中数据”争议。消息层面，此前，康方生物发布公告称，依沃西单抗第二个适应症获得国家药监局的批准上市。在依沃西新适应症获批的同时，康方生物的合作伙伴Summit股价一度跌超36%。去年5月30日，康方已完成PFS的分析，并在7月26日提交上市申请，当时未对OS进行期中分析，因这不是试验主要目的。截至4月30日收盘，康方生物股价下跌1.2%，收报86.25港元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430205635a46dbd8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430205635a46dbd8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","BK1161","LU0348784397.USD","LU1720050803.USD","IE00B543WZ88.USD","LU0348783233.USD","LU0417516571.SGD","LU2488822045.USD","09926","LU1794554557.SGD"],"gpt_icon":1},{"id":"2531130034","title":"加科思-B(01167)：一致行動人士可行使的投票權由約26.67%變為約25.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531130034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531130034?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 20:20","pubTimestamp":1746015647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，因部分已从集团离职的人士(“离职人士”)持有公司的股份权益已经不再被视为公司一致行动人士，截至本公告日期，一致行动人士可行使的投票权由约26.67%变为约25.21%，且一致行动人士仍为公司最大单一股东集团。公司收到离职人士的通知，为了表达对公司长期价值的信心，离职人士向公司就其于有关股份中直接及间接持有的权益，自愿作出1年的禁售承诺。禁售承诺自本公告日期起生效，至2026年5月1日终止。公司董事会认为一致行动人的权益变动不会影响公司的经营策略和长期发展规划。公司将继续致力于提升经营业绩，为公司股东创造持续增长的价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2531039409","title":"德商銀行：歐元區經濟增長勢頭可能轉瞬即逝","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039409","media":"金十财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039409?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 20:05","pubTimestamp":1746014721,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://flash-api.jin10.com/get_flash_list?channel=2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_jinshicaijing","symbols":["BK4213","161121","BK1191","BK1574","01477","GDP"],"gpt_icon":0},{"id":"2531035965","title":"康寧傑瑞製藥-B(09966)：KN026關鍵性II/III期臨牀試驗期中分析達到PFS主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2531035965","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531035965?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，本公司与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的KN026联合化疗二线及以上治疗HER2阳性GC的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001研究第2部分的首个PFS期中分析结果已由独立数据监察委员会 审查，结果显示达到预先设定的PFS的主要终点，具有统计学显著性和临床意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1576","BK4211","03347","III","BK4195","BK1583","09966","BK4134","BK1574","BK1141","PFS"],"gpt_icon":0},{"id":"2531038672","title":"歌禮制藥-B(01672)因購股權獲行使合計發行4.7萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531038672","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531038672?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 19:06","pubTimestamp":1746011194,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，由于合资格参与者根据本公司于2019年6月6日采纳的购股权计划行使购股权，本公司于2025年4月30日发行1.8万股普通股。由于合资格参与者根据本公司于2019年6月6日采纳的购股权计划行使购股权，本公司于2025年4月30日发行2.2万股普通股。由于合资格参与者根据本公司于2019年6月6日采纳的购股权计划行使购股权，本公司于2025年4月30日发行7000股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","BK1191","01672","01477"],"gpt_icon":0},{"id":"2531080318","title":"和鉑醫藥-B(02142)4月30日斥資231.56萬港元回購27萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531080318","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531080318?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 18:53","pubTimestamp":1746010387,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，该公司于2025年4月30日斥资231.56万港元回购27万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)4月30日斥资231.56万港元回购27万股","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1161","02142"],"gpt_icon":0},{"id":"2531080466","title":"新諾威76億併購涼了，155億“石家莊大佬”還要死磕創新藥？","url":"https://stock-news.laohu8.com/highlight/detail?id=2531080466","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531080466?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 18:32","pubTimestamp":1746009120,"startTime":"0","endTime":"0","summary":"　　新诺威频繁收购大股东资产，收效如何？　　4月28日，新诺威一纸公告宣布终止收购石药集团百克（山东）生物制药股份有限公司100%股权。　　而此前，作为石药集团旗下核心上市公司，新诺威多次收购石药集团旗下资产，2024年1月更通过完成收购巨石生物，跨界转型创新药领域。但目前，巨额研发投入导致新诺威业绩下降，巨石生物还尚未盈利。截至4月30日，新诺威股价报41.91元/股，上涨5.83%，总市值589亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-04-30/doc-ineuyanw6981955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","159992","300765","06978","BK0226"],"gpt_icon":0},{"id":"2531081843","title":"每日賣空追蹤 | 康寧傑瑞製藥-B 04月30日賣空量成交2000股，賣空比例為0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531081843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531081843?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:49","pubTimestamp":1746006579,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间04月30日，跌3.58%，卖空量成交2000股，较上一交易日减少90.48%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430175913a6ceaa26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430175913a6ceaa26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2531084212","title":"每日賣空追蹤 | 科濟藥業-B 04月30日賣空量成交9萬股，賣空比例為7.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531084212?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:49","pubTimestamp":1746006564,"startTime":"0","endTime":"0","summary":"科济药业-B北京时间04月30日，跌2.75%，卖空量成交9万股，较上一交易日减少14.29%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430175533a46d82af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430175533a46d82af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","02171","BK1574","BK1587","BK1161"],"gpt_icon":0},{"id":"2531084404","title":"每日賣空追蹤 | 雲頂新耀-B 04月30日賣空量成交52.05萬股，賣空比例為9.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084404","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531084404?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:49","pubTimestamp":1746006562,"startTime":"0","endTime":"0","summary":"云顶新耀-B北京时间04月30日，涨0.61%，卖空量成交52.05万股，较上一交易日减少15.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430175446a6cea849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430175446a6cea849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2531083470","title":"華仁藥業(300110.SZ)子公司取得一項醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2531083470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531083470?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:27","pubTimestamp":1746005222,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华仁药业(300110.SZ)公告，公司全资子公司青岛华仁医疗用品有限公司收到山东省药品监督管理局核准签发的“医用创面敷料”的《医疗器械注册证》，该产品适用于非慢性创面(如浅表性创面、激光/光子/果酸换肤后的创面)及周围皮肤的护理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300110","BK1583","159883","BK0102","09996","BK1222","09997","BK1574","BK0239","BK1100"],"gpt_icon":0},{"id":"2531085785","title":"榮昌生物：2022年A股限制性股票激勵計劃部分權益歸屬完成暨上市公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085785","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531085785?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:25","pubTimestamp":1746005158,"startTime":"0","endTime":"0","summary":"荣昌生物公告，公司已完成2022年A股限制性股票激励计划中A类权益第二个及B类权益首次授予第一个归属期的归属工作，涉及16名A类和100名B类激励对象，共计归属27.6160万股。新增股份于2025年5月8日上市流通，总股本增至54460.824万股。本次归属不会对公司财务状况和经营成果构成重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430174055a46d7e89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430174055a46d7e89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","LU2328871848.SGD","688331","BK1161","LU1969619763.USD","BK1583","BK1574"],"gpt_icon":0},{"id":"2531860580","title":"對話於邱黎陽：讓科學家參與投資把關，能夠促成生命健康產業“投早投小”","url":"https://stock-news.laohu8.com/highlight/detail?id=2531860580","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531860580?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:07","pubTimestamp":1746004072,"startTime":"0","endTime":"0","summary":"2021年，我国国产新药的上市数量首次超过进口药；艾昆纬（IQVIA）发布的《2024年全球研发趋势报告》显示，近五年中国新药上市量仅次于美国。近年来，我国生命健康产业，尤其是医药企业正在从“跟随性创新”向“源头创新”转变。不过，我国生物医药领域的源头创新资源更多集中在高校和科研院所，如何让科研成果从实验室走向产业园，依然是当前亟待解决的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504303394561138.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504303394561138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09939","BK1515","BK1161"],"gpt_icon":0},{"id":"2531702370","title":"【華仁藥業：子公司取得醫療器械註冊證】華仁藥業公告，全資子公司青島華仁醫療用品有限公司收到山東省藥品監督管理局核准簽發的“醫用創面敷料”的《醫療器械註冊證》。該產品適用於非慢性創面及周圍皮膚護理，包含15個型號規格。目前國內擁有同類上市產品的企業共22家。本次取得註冊證將豐富公司醫療器械產品線，提高競爭力，助力公司原料藥、製劑、醫療器械、醫用包材等板塊的協同發展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531702370","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531702370?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:41","pubTimestamp":1746002470,"startTime":"0","endTime":"0","summary":"华仁药业公告，全资子公司青岛华仁医疗用品有限公司收到山东省药品监督管理局核准签发的“医用创面敷料”的《医疗器械注册证》。该产品适用于非慢性创面及周围皮肤护理，包含15个型号规格。目前国内拥有同类上市产品的企业共22家。本次取得注册证将丰富公司医疗器械产品线，提高竞争力，助力公司原料药、制剂、医疗器械、医用包材等板块的协同发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30164150044124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300110","BK1574","09996","BK0102","159891","09997","BK1100","BK1222","BK0239","BK1583","159883"],"gpt_icon":0},{"id":"2531089032","title":"康哲藥業擬分拆德鎂醫藥上市，聚焦皮膚健康駛入增長“快車道”","url":"https://stock-news.laohu8.com/highlight/detail?id=2531089032","media":"环球财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531089032?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:39","pubTimestamp":1746002384,"startTime":"0","endTime":"0","summary":"近日，康哲药业建议启动分拆，拟推动旗下皮肤业务子公司德镁医药于香港联交所主板独立上市，引发资本市场广泛关注。2024年，其皮肤处方药收入亦排名首位。值得注意的是，德镁医药2024年皮肤学级护肤品收入同比增长68%，占比提升至13%，显示出其“药妆协同”战略的成效。随着更多核心产品获批、渠道拓展深化，德镁医药有望进一步夯实其在皮肤健康赛道的领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430164718974b5635&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430164718974b5635&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","09939","BK1574","SG9999004220.SGD","BK1161","SG9999015945.SGD","IE00BMCWC346.EUR","BK1515","SG9999015986.USD","LU2488822045.USD","SG9999015952.SGD","IE00BYV24P56.USD","BK1191","BK1593","SG9999015978.USD"],"gpt_icon":0},{"id":"2531508472","title":"康希諾生物04月30日主力淨流入393.0萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2531508472","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531508472?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000951,"startTime":"0","endTime":"0","summary":"04月30日, 康希诺生物股价涨11.68%，报收33.95元，成交金额1.1亿元，换手率2.50%，振幅13.32%，量比4.04。康希诺生物今日主力资金净流入393.0万元，上一交易日主力净流出101.5万元。该股近5个交易日上涨9.69%，主力资金累计净流入184.6万元；近20日主力资金累计净流入1992.6万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171355a6ce9c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171355a6ce9c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06185","BK1161","BK1515","BK1191"],"gpt_icon":0},{"id":"2531085426","title":"基石藥業-B04月30日主力淨流出5.0萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085426","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531085426?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000939,"startTime":"0","endTime":"0","summary":"04月30日, 基石药业-B股价跌1.40%，报收2.82元，成交金额493.4万元，换手率0.13%，振幅4.90%，量比0.31。基石药业-B今日主力资金净流出5.0万元，上一交易日主力净流入70.9万元。该股近5个交易日下跌6.90%，主力资金累计净流出333.3万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1777.8万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171016a46d754f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171016a46d754f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":34,"pageCount":1,"totalSize":673,"code":"91000000","status":"200"}]}}